Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Dror Michaelson

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
Journal of Oncology Practice|January 9, 2014
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancerAyal A Aizer, Jonathan J Paly, M Dror Michaelson, et al.
Clinical Genitourinary Cancer|July 17, 2017
Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical TrialsNizar M Tannir, Robert A Figlin, Martin E Gore, et al.
American Journal of Physiology. Renal Physiology|December 2, 2004
Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopyRachel Katz-Brull, Neil M Rofsky, Martina M Morrin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2009
Phase II study of sunitinib in men with advanced prostate cancerM Dror Michaelson, M M Regan, W K Oh, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 18, 2024
Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate CancerTimothy W Churchill, Matthew R Smith, M Dror Michaelson, et al.
Cancer|June 11, 2015
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinomaM Dror Michaelson, Rana R McKay, Lillian Werner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone MetastasesRana R McKay, Dominick Bossé, Kathryn P Gray, et al.
British Journal of Cancer|October 23, 2015
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patientsFrede Donskov, M Dror Michaelson, Igor Puzanov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II StudyMichael B Atkins, Gwenaelle Gravis, Kazimierz Drosik, et al.
The Journal of Urology|September 18, 2007
Sunitinib efficacy against advanced renal cell carcinomaRobert J Motzer, M Dror Michaelson, Jonathan Rosenberg, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
Journal of Oncology Practice|January 9, 2014
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancerAyal A Aizer, Jonathan J Paly, M Dror Michaelson, et al.
Clinical Genitourinary Cancer|July 17, 2017
Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical TrialsNizar M Tannir, Robert A Figlin, Martin E Gore, et al.
American Journal of Physiology. Renal Physiology|December 2, 2004
Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopyRachel Katz-Brull, Neil M Rofsky, Martina M Morrin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2009
Phase II study of sunitinib in men with advanced prostate cancerM Dror Michaelson, M M Regan, W K Oh, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 18, 2024
Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate CancerTimothy W Churchill, Matthew R Smith, M Dror Michaelson, et al.
Cancer|June 11, 2015
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinomaM Dror Michaelson, Rana R McKay, Lillian Werner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone MetastasesRana R McKay, Dominick Bossé, Kathryn P Gray, et al.
British Journal of Cancer|October 23, 2015
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patientsFrede Donskov, M Dror Michaelson, Igor Puzanov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II StudyMichael B Atkins, Gwenaelle Gravis, Kazimierz Drosik, et al.
The Journal of Urology|September 18, 2007
Sunitinib efficacy against advanced renal cell carcinomaRobert J Motzer, M Dror Michaelson, Jonathan Rosenberg, et al.
Pageof 12